{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-237150","form_type":"8-K","ticker":"TPST","cik":"0001544227","company_name":"Tempest Therapeutics, Inc.","filed_at":"2026-05-22T21:05:53+00:00","discovered_at":"2026-05-22T21:08:00.250910+00:00","generated_at":"2026-05-22T21:09:46.337732+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.4,"confidence":"high","headline":"Three directors resign from Tempest Therapeutics board effective May 22, 2026","bullets":["Stephen Brady, Michael Raab, and Christine Pellizzari resigned from the Tempest board on May 22, 2026.","Resignations not due to any disagreement with the company on operations, policies, or practices.","Separation agreements waive accrued unpaid director retainer fees; stock options and indemnification remain.","Board size reduced by three members; no replacements announced."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-237150","json":"https://secwatch.observer/filing/0001193125-26-237150.json","markdown":"https://secwatch.observer/filing/0001193125-26-237150.md","text":"https://secwatch.observer/filing/0001193125-26-237150.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526237150/0001193125-26-237150-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526237150/d29824d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T21:09:46.337732+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5310339e24","claim":"Christine Pellizzari resigned as Director at Tempest Therapeutics, Inc..","evidence_excerpt":"On May 22, 2026, each of Mr. Stephen Brady, Mr. Michael Raab and Ms. Christine Pellizzari notified Tempest Therapeutics, Inc. (the “Company”) of his or her resignation from the Board of Directors of the Company (the “Board”), effective as of such date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526237150/0001193125-26-237150-index.htm","confidence":0.95},{"claim_id":"6b76a16d94","claim":"Michael Raab resigned as Director at Tempest Therapeutics, Inc..","evidence_excerpt":"On May 22, 2026, each of Mr. Stephen Brady, Mr. Michael Raab and Ms. Christine Pellizzari notified Tempest Therapeutics, Inc. (the “Company”) of his or her resignation from the Board of Directors of the Company (the “Board”), effective as of such date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526237150/0001193125-26-237150-index.htm","confidence":0.95},{"claim_id":"7d5fc56857","claim":"Stephen Brady resigned as Director at Tempest Therapeutics, Inc..","evidence_excerpt":"On May 22, 2026, each of Mr. Stephen Brady, Mr. Michael Raab and Ms. Christine Pellizzari notified Tempest Therapeutics, Inc. (the “Company”) of his or her resignation from the Board of Directors of the Company (the “Board”), effective as of such date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526237150/0001193125-26-237150-index.htm","confidence":0.95}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}